Julie O'Neill was appointed as non-executive chair at HOOKIPA Pharma Inc..
“the Company’s board of directors (the “Board”) appointed Julie O’Neill to serve as non-executive chair of the Board, effective as of the Effective Time.”
HOOKIPA Pharma Inc. — fact timeline
Source-grounded facts extracted from HOOKIPA Pharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Timothy Reilly resigned as director at HOOKIPA Pharma Inc..
“On August 27, 2024, Timothy Reilly, Ph.D., notified the Company of his resignation as a director of the Company, effective as of the Effective Time.”
Jan van de Winkel resigned as director at HOOKIPA Pharma Inc..
“On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time”
Malte Peters was appointed as Chief Executive Officer and President at HOOKIPA Pharma Inc..
“the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.”
Reinhard Kandera resigned as Director at HOOKIPA Pharma Inc..
“Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer”
Reinhard Kandera departed as Chief Financial Officer at HOOKIPA Pharma Inc..
“On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.”
Joern Aldag resigned as Director at HOOKIPA Pharma Inc..
“Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer”
Joern Aldag departed as Chief Executive Officer at HOOKIPA Pharma Inc..
“On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).”
HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.
“Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.”
HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.
“On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.